Comparative Analysis of the Therapeutic Effects of Fresh and Cryopreserved Human Umbilical Cord Derived Mesenchymal Stem Cells in the Treatment of Psoriasis
- PMID: 37199874
- DOI: 10.1007/s12015-023-10556-8
Comparative Analysis of the Therapeutic Effects of Fresh and Cryopreserved Human Umbilical Cord Derived Mesenchymal Stem Cells in the Treatment of Psoriasis
Abstract
Psoriasis, an inflammatory autoimmune skin disease, is characterized by scaly white or erythematous plaques, which severely influence patients' quality of life and social activities. Mesenchymal stem cells derived from the human umbilical cord (UCMSCs) represent a promising therapeutic approach for psoriasis because of its unique superiority in ethical agreeableness, abundant source, high proliferation capacity, and immunosuppression. Although cryopreservation provided multiple benefits to the cell therapy, it also greatly compromised clinical benefits of MSCs due to impaired cell functions. The current study aims to evaluate the therapeutic efficacy of cryopreserved UCMSCs in a mouse model of psoriasis as well as in patients with psoriasis. Our results showed that cryopreserved and fresh UCMSCs have comparable effects on the suppression of psoriasis-like symptoms such as thickening, erythema, and scaling, and serum IL-17 A secretion in mice model of psoriasis. Moreover, psoriatic patients injected with cryopreserved UCMSCs had a significant improvement in the Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), and Patient Global Assessments (PtGAs) scores compared to baseline values. Mechanically, cryopreserved UCMSCs markedly inhibit the proliferation of PHA-activated PBMCs, type 1 T helper (Th1) and type 17 T helper (Th17) cell differentiation and secretion of inflammatory cytokines including IFN-γ, TNF-a and IL-17 A in PBMCs stimulated by anti-CD3/CD28 beads. Taken together, these data indicated that cryopreserved UCMSCs exhibited great beneficial effect on psoriasis. Thus, cryopreserved UCMSCs can be systemically administered as ''off-the-shelf'' cell product for psoriasis therapy. Trial Registration ChiCTR1800019509. Registered on November 15, 2018-Retrospectively registered, http://www.chictr.org.cn/ .
Keywords: Autoimmune disease; Cell therapy; Mesenchymal stem cells; Perinatal tissues; Psoriasis.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Comparison of umbilical cord tissue-derived mesenchymal stromal cells isolated from cryopreserved material and extracted by explantation and digestion methods utilizing a split manufacturing model.Cytotherapy. 2020 Oct;22(10):581-591. doi: 10.1016/j.jcyt.2020.06.002. Epub 2020 Jul 25. Cytotherapy. 2020. PMID: 32718875
-
Human umbilical cord-derived mesenchymal stem cells ameliorate psoriasis-like dermatitis by suppressing IL-17-producing γδ T cells.Cell Tissue Res. 2022 Jun;388(3):549-563. doi: 10.1007/s00441-022-03616-x. Epub 2022 Mar 26. Cell Tissue Res. 2022. PMID: 35347409
-
Indirubin combined with umbilical cord mesenchymal stem cells to relieve psoriasis-like skin lesions in BALB/c mice.Front Immunol. 2022 Nov 16;13:1033498. doi: 10.3389/fimmu.2022.1033498. eCollection 2022. Front Immunol. 2022. PMID: 36466901 Free PMC article.
-
Bioactive molecules derived from umbilical cord mesenchymal stem cells.Acta Histochem. 2016 Oct;118(8):761-769. doi: 10.1016/j.acthis.2016.09.006. Epub 2016 Sep 28. Acta Histochem. 2016. PMID: 27692875 Review.
-
miRNA-Guided Regulation of Mesenchymal Stem Cells Derived from the Umbilical Cord: Paving the Way for Stem-Cell Based Regeneration and Therapy.Int J Mol Sci. 2023 May 24;24(11):9189. doi: 10.3390/ijms24119189. Int J Mol Sci. 2023. PMID: 37298143 Free PMC article. Review.
Cited by
-
Harnessing the Anti-Inflammatory Effects of Perinatal Tissue Derived Therapies for the Treatment of Inflammatory Skin Diseases: A Comprehensive Review.Stem Cell Rev Rep. 2025 Feb;21(2):351-371. doi: 10.1007/s12015-024-10822-3. Epub 2024 Nov 12. Stem Cell Rev Rep. 2025. PMID: 39531196 Review.
-
Expert Consensus on the Application of Stem Cells in Psoriasis Research and Clinical Trials.Aging Dis. 2024 Jun 4;16(3):1363-1377. doi: 10.14336/AD.2024.0012. Aging Dis. 2024. PMID: 39012666 Free PMC article. Review.
-
Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Autoimmune Diseases.Clin Rev Allergy Immunol. 2025 Feb 21;68(1):21. doi: 10.1007/s12016-025-09030-9. Clin Rev Allergy Immunol. 2025. PMID: 39982546 Review.
-
Efficacy and Mechanism of Highly Active Umbilical Cord Mesenchymal Stem Cells in the Treatment of Osteoporosis in Rats.Curr Stem Cell Res Ther. 2025;20(1):91-102. doi: 10.2174/011574888X284911240131100909. Curr Stem Cell Res Ther. 2025. PMID: 38357953
-
Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases.Immun Inflamm Dis. 2025 May;13(5):e70189. doi: 10.1002/iid3.70189. Immun Inflamm Dis. 2025. PMID: 40353645 Free PMC article. Review.
References
-
- Zhou, X., Chen, Y., Cui, L., Shi, Y., & Guo, C. (2022). Advances in the pathogenesis of psoriasis: From keratinocyte perspective. Cell Death & Disease, 13, 81. - DOI
-
- Chiricozzi, A., Guttman-Yassky, E., Suárez-Fariñas, M., Nograles, K. E., Tian, S., Cardinale, I., Chimenti, S., & Krueger, J. G. (2011). Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. The Journal of Investigative Dermatology, 131, 677–687. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical